{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T04:27:10Z","timestamp":1776140830383,"version":"3.50.1"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,3,22]],"date-time":"2022-03-22T00:00:00Z","timestamp":1647907200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,3,22]],"date-time":"2022-03-22T00:00:00Z","timestamp":1647907200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Pediatr"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Severe fatal human adenoviral (HAdV) pneumonia is associated with significant mortality and no effective drug is available for clinical therapy. We evaluated the association and safety of high titer neutralizing antibodies (NAbs) plasma in pediatric patients with severe fatal HAdV pneumonia.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>A retrospective cohort study was performed between January 2016 to June 2021 in pediatric intensive care unit. Pediatric patients with severe fatal HAdV pneumonia were included and divided into plasma group (conventional treatment plus high titer NAbs plasma treatment) and control group (conventional treatment alone). The primary outcome was mortality in hospital. Secondary outcomes were the duration of fever after adenovirus genotype determined, duration of invasive mechanical ventilation, length of hospital stay. T-test, Mann-Whitney U-test, chi-square test, univariable and multivariable logistic regression analysis, Kaplan-Meier method and log-rank test were adopted to compare differences between two groups.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>A total of 59 pediatric patients with severe fatal HAdV pneumonia were enrolled. They were divided into plasma group (<jats:italic>n<\/jats:italic>\u2009=\u200933) and control group (<jats:italic>n<\/jats:italic>\u2009=\u200926). The mortality in hospital was 28.8% (17\/ 59). Significantly fewer patients progressed to death in plasma group than control group (18.2% vs 42.3%, <jats:italic>p<\/jats:italic>\u2009=\u20090.042). Sequential organ failure assessment (SOFA) score, oxygen index (OI) and high titer NAbs plasma treatment were included in multivariable logistic regression analysis for mortality risk factors. Consequentially, SOFA score (Hazard Ratio [HR] 7.686, 95% Confidence Interval [CI] 1.735\u201334.054, <jats:italic>p<\/jats:italic>\u2009=\u20090.007) and without high titer NAbs plasma treatment (HR 4.298, 95%CI 1.030\u201317.934, <jats:italic>p<\/jats:italic>\u2009=\u20090.045) were significantly associated with mortality. In addition, high titer NAbs plasma treatment were associated with faster temperature recovering in survivors (<jats:italic>p<\/jats:italic>\u2009=\u20090.031). No serious adverse effects occurred.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Administration of high titer NAbs plasma were associated with a lower hazard for mortality in pediatric patients with severe fatal HAdV pneumonia. For survivors, high titer NAbs plasma treatment shorten the duration of fever.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12887-022-03225-1","type":"journal-article","created":{"date-parts":[[2022,3,22]],"date-time":"2022-03-22T04:02:35Z","timestamp":1647921755000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Mortality reduction in pediatric patients with severe fatal human adenoviral pneumonia treated with high titer neutralizing antibodies (NAbs) plasma: a retrospective cohort study"],"prefix":"10.1186","volume":"22","author":[{"given":"Hongyan","family":"Peng","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Feiyan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yunlong","family":"Zuo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bolun","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yiyu","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Run","family":"Dang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,3,22]]},"reference":[{"issue":"4","key":"3225_CR1","doi-asserted-by":"publisher","first-page":"e123234","DOI":"10.1371\/journal.pone.0123234","volume":"10","author":"Y Li","year":"2015","unstructured":"Li Y, Zhou W, Zhao Y, Wang Y, Xie Z, Lou Y, et al. Molecular typing and epidemiology profiles of human adenovirus infection among paediatric patients with severe acute respiratory infection in China. PLoS One. 2015;10(4):e123234. https:\/\/doi.org\/10.1371\/journal.pone.0123234.","journal-title":"PLoS One"},{"issue":"4","key":"3225_CR2","doi-asserted-by":"publisher","first-page":"e2189","DOI":"10.1002\/rmv.2189","volume":"31","author":"VM Pscheidt","year":"2021","unstructured":"Pscheidt VM, Gregianini TS, Martins LG, Veiga A. Epidemiology of human adenovirus associated with respiratory infection in southern Brazil. Rev Med Virol. 2021;31(4):e2189. https:\/\/doi.org\/10.1002\/rmv.2189.","journal-title":"Rev Med Virol"},{"issue":"6","key":"3225_CR3","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1007\/s00134-013-2893-0","volume":"39","author":"MC Spaeder","year":"2013","unstructured":"Spaeder MC. Severe adenoviral respiratory infection in children. Intensive Care Med. 2013;39(6):1157\u20138. https:\/\/doi.org\/10.1007\/s00134-013-2893-0.","journal-title":"Intensive Care Med"},{"issue":"3","key":"3225_CR4","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1007\/s12250-020-00307-1","volume":"36","author":"X Tian","year":"2021","unstructured":"Tian X, Fan Y, Wang C, Liu Z, Liu W, Xu Y, et al. Seroprevalence of neutralizing antibodies against six human adenovirus types indicates the low level of herd immunity in young children from Guangzhou. China Virol Sin. 2021;36(3):373\u201381. https:\/\/doi.org\/10.1007\/s12250-020-00307-1.","journal-title":"China Virol Sin"},{"issue":"10","key":"3225_CR5","doi-asserted-by":"publisher","first-page":"e205795","DOI":"10.1371\/journal.pone.0205795","volume":"13","author":"L Li","year":"2018","unstructured":"Li L, Woo YY, de Bruyne JA, Nathan AM, Kee SY, Chan YF, et al. Epidemiology, clinical presentation and respiratory sequelae of adenovirus pneumonia in children in Kuala Lumpur, Malaysia. PLoS One. 2018;13(10):e205795. https:\/\/doi.org\/10.1371\/journal.pone.0205795.","journal-title":"PLoS One"},{"key":"3225_CR6","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1186\/1471-2334-12-55","volume":"12","author":"S Alharbi","year":"2012","unstructured":"Alharbi S, Van Caeseele P, Consunji-Araneta R, et al. Epidemiology of severe pediatric adenovirus lower respiratory tract infections in Manitoba, Canada, 1991-2005. BMC Infect Dis. 2012;12:55. https:\/\/doi.org\/10.1186\/1471-2334-12-55.","journal-title":"BMC Infect Dis"},{"issue":"17","key":"3225_CR7","doi-asserted-by":"publisher","first-page":"9490","DOI":"10.1073\/pnas.2004168117","volume":"117","author":"K Duan","year":"2020","unstructured":"Duan K, Liu B, Li C, Zhang H, Yu T, Qu J, et al. Effectiveness of convalescent plasma therapy in severe COVID-19 patients. Proc Natl Acad Sci U S A. 2020;117(17):9490\u20136. https:\/\/doi.org\/10.1073\/pnas.2004168117.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"11","key":"3225_CR8","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1016\/S2213-2600(19)30253-X","volume":"7","author":"RJ Davey","year":"2019","unstructured":"Davey RJ, Fernandez-Cruz E, Markowitz N, Pett S, Babiker AG, Wentworth D, et al. Anti-influenza hyperimmune intravenous immunoglobulin for adults with influenza a or B infection (FLU-IVIG): a double-blind, randomised, placebo-controlled trial. Lancet Respir Med. 2019;7(11):951\u201363. https:\/\/doi.org\/10.1016\/S2213-2600(19)30253-X.","journal-title":"Lancet Respir Med"},{"issue":"9","key":"3225_CR9","doi-asserted-by":"publisher","first-page":"1554","DOI":"10.3201\/eid2209.151164","volume":"22","author":"YM Arabi","year":"2016","unstructured":"Arabi YM, Hajeer AH, Luke T, Raviprakash K, Balkhy H, Johani S, et al. Feasibility of using convalescent plasma immunotherapy for MERS-CoV infection, Saudi Arabia. Emerg Infect Dis. 2016;22(9):1554\u201361. https:\/\/doi.org\/10.3201\/eid2209.151164.","journal-title":"Emerg Infect Dis"},{"issue":"5","key":"3225_CR10","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1093\/jac\/dki346","volume":"56","author":"KM Yeh","year":"2005","unstructured":"Yeh KM, Chiueh TS, Siu LK, Lin JC, Chan PK, Peng MY, et al. Experience of using convalescent plasma for severe acute respiratory syndrome among healthcare workers in a Taiwan hospital. J Antimicrob Chemother. 2005;56(5):919\u201322. https:\/\/doi.org\/10.1093\/jac\/dki346.","journal-title":"J Antimicrob Chemother"},{"issue":"1","key":"3225_CR11","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1093\/infdis\/jiu396","volume":"211","author":"J Mair-Jenkins","year":"2015","unstructured":"Mair-Jenkins J, Saavedra-Campos M, Baillie JK, Cleary P, Khaw FM, Lim WS, et al. The effectiveness of convalescent plasma and hyperimmune immunoglobulin for the treatment of severe acute respiratory infections of viral etiology: a systematic review and exploratory meta-analysis. J Infect Dis. 2015;211(1):80\u201390. https:\/\/doi.org\/10.1093\/infdis\/jiu396.","journal-title":"J Infect Dis"},{"issue":"4","key":"3225_CR12","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1111\/bjh.17272","volume":"192","author":"AG Shenoy","year":"2021","unstructured":"Shenoy AG, Hettinger AZ, Fernandez SJ, Blumenthal J, Baez V. Early mortality benefit with COVID-19 convalescent plasma: a matched control study. Br J Haematol. 2021;192(4):706\u201313. https:\/\/doi.org\/10.1111\/bjh.17272.","journal-title":"Br J Haematol"},{"issue":"5","key":"3225_CR13","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1097\/PCC.0000000000000350","volume":"16","author":"Pediatric acute respiratory distress syndrome","year":"2015","unstructured":"Pediatric acute respiratory distress syndrome. Consensus recommendations from the pediatric acute lung injury consensus conference. Pediatr Crit Care Med. 2015;16(5):428\u201339. https:\/\/doi.org\/10.1097\/PCC.0000000000000350.","journal-title":"Pediatr Crit Care Med"},{"issue":"3","key":"3225_CR14","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1164\/ajrccm\/138.3.720","volume":"138","author":"JF Murray","year":"1988","unstructured":"Murray JF, Matthay MA, Luce JM, Flick MR. An expanded definition of the adult respiratory distress syndrome. Am Rev Respir Dis. 1988;138(3):720\u20133. https:\/\/doi.org\/10.1164\/ajrccm\/138.3.720.","journal-title":"Am Rev Respir Dis"},{"key":"3225_CR15","first-page":"1260","volume-title":"Zhufutang practical pediatrics (8th edition) [M]","author":"ZF Jiang","year":"2014","unstructured":"Jiang ZF, Shen KL, Shen Y. Zhufutang practical pediatrics (8th edition) [M]. Beijing: People's Medical Publishing House; 2014. p. 1260\u20132."},{"issue":"6","key":"3225_CR16","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1016\/S2213-2600(17)30174-1","volume":"5","author":"JH Beigel","year":"2017","unstructured":"Beigel JH, Tebas P, Elie-Turenne MC, Bajwa E, Bell TE, Cairns CB, et al. Immune plasma for the treatment of severe influenza: an open-label, multicentre, phase 2 randomised study. Lancet Respir Med. 2017;5(6):500\u201311. https:\/\/doi.org\/10.1016\/S2213-2600(17)30174-1.","journal-title":"Lancet Respir Med"},{"key":"3225_CR17","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1016\/j.ijid.2020.11.198","volume":"103","author":"S Alsharidah","year":"2021","unstructured":"Alsharidah S, Ayed M, Ameen RM, Alhuraish F, Rouheldeen NA, Alshammari FR, et al. COVID-19 convalescent plasma treatment of moderate and severe cases of SARS-CoV-2 infection: a multicenter interventional study. Int J Infect Dis. 2021;103:439\u201346. https:\/\/doi.org\/10.1016\/j.ijid.2020.11.198.","journal-title":"Int J Infect Dis"},{"issue":"1","key":"3225_CR18","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1056\/NEJMoa1511812","volume":"374","author":"J van Griensven","year":"2016","unstructured":"van Griensven J, Edwards T, de Lamballerie X, Semple MG, Gallian P, Baize S, et al. Evaluation of convalescent plasma for Ebola virus disease in Guinea. N Engl J Med. 2016;374(1):33\u201342. https:\/\/doi.org\/10.1056\/NEJMoa1511812.","journal-title":"N Engl J Med"},{"issue":"1","key":"3225_CR19","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1093\/infdis\/jiaa228","volume":"222","author":"QL Zeng","year":"2020","unstructured":"Zeng QL, Yu ZJ, Gou JJ, Li GM, Ma SH, Zhang GF, et al. Effect of convalescent plasma therapy on viral shedding and survival in patients with coronavirus disease 2019. J Infect Dis. 2020;222(1):38\u201343. https:\/\/doi.org\/10.1093\/infdis\/jiaa228.","journal-title":"J Infect Dis"},{"issue":"1","key":"3225_CR20","doi-asserted-by":"publisher","first-page":"14","DOI":"10.3760\/cma.j.cn112140-20200704-00687","volume":"59","author":"H Huang","year":"2021","unstructured":"Huang H, Chen Y, Ma LY, et al. Analysis of the clinical features and the risk factors of severe adenovirus pneumonia in children. Zhonghua Er Ke Za Zhi. 2021;59(1):14\u20139. https:\/\/doi.org\/10.3760\/cma.j.cn112140-20200704-00687.","journal-title":"Zhonghua Er Ke Za Zhi"},{"issue":"11","key":"3225_CR21","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1056\/NEJMoa2031893","volume":"384","author":"MJ Joyner","year":"2021","unstructured":"Joyner MJ, Carter RE, Senefeld JW, Klassen SA, Mills JR, Johnson PW, et al. Convalescent plasma antibody levels and the risk of death from Covid-19. N Engl J Med. 2021;384(11):1015\u201327. https:\/\/doi.org\/10.1056\/NEJMoa2031893.","journal-title":"N Engl J Med"},{"issue":"4","key":"3225_CR22","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1093\/infdis\/jiy199","volume":"218","author":"JF Brown","year":"2018","unstructured":"Brown JF, Dye JM, Tozay S, Jeh-Mulbah G, Wohl DA, Fischer WN, et al. Anti-Ebola virus antibody levels in convalescent plasma and viral load after plasma infusion in patients with Ebola virus disease. J Infect Dis. 2018;218(4):555\u201362. https:\/\/doi.org\/10.1093\/infdis\/jiy199.","journal-title":"J Infect Dis"},{"key":"3225_CR23","doi-asserted-by":"publisher","first-page":"102598","DOI":"10.1016\/j.jaut.2021.102598","volume":"118","author":"Y Acosta-Ampudia","year":"2021","unstructured":"Acosta-Ampudia Y, Monsalve DM, Rojas M, Rodriguez Y, Gallo JE, Salazar-Uribe JC, et al. COVID-19 convalescent plasma composition and immunological effects in severe patients. J Autoimmun. 2021;118:102598. https:\/\/doi.org\/10.1016\/j.jaut.2021.102598.","journal-title":"J Autoimmun"},{"issue":"6 Suppl 1","key":"3225_CR24","doi-asserted-by":"publisher","first-page":"S7","DOI":"10.1097\/TA.0000000000000630","volume":"78","author":"DR Potter","year":"2015","unstructured":"Potter DR, Baimukanova G, Keating SM, Deng X, Chu JA, Gibb SL, et al. Fresh frozen plasma and spray-dried plasma mitigate pulmonary vascular permeability and inflammation in hemorrhagic shock. J Trauma Acute Care Surg. 2015;78(6 Suppl 1):S7\u201317. https:\/\/doi.org\/10.1097\/TA.0000000000000630.","journal-title":"J Trauma Acute Care Surg"},{"issue":"2","key":"3225_CR25","doi-asserted-by":"publisher","first-page":"e2162","DOI":"10.1002\/rmv.2162","volume":"31","author":"EO Murchu","year":"2021","unstructured":"Murchu EO, Byrne P, Walsh KA, et al. Immune response following infection with SARS-CoV-2 and other coronaviruses: a rapid review. Rev Med Virol. 2021;31(2):e2162. https:\/\/doi.org\/10.1002\/rmv.2162.","journal-title":"Rev Med Virol"},{"issue":"1","key":"3225_CR26","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1007\/s10096-004-1271-9","volume":"24","author":"Y Cheng","year":"2005","unstructured":"Cheng Y, Wong R, Soo YO, Wong WS, Lee CK, Ng MH, et al. Use of convalescent plasma therapy in SARS patients in Hong Kong. Eur J Clin Microbiol Infect Dis. 2005;24(1):44\u20136. https:\/\/doi.org\/10.1007\/s10096-004-1271-9.","journal-title":"Eur J Clin Microbiol Infect Dis"},{"issue":"3","key":"3225_CR27","doi-asserted-by":"publisher","first-page":"362","DOI":"10.2450\/2014.0156-13","volume":"12","author":"N Mafirakureva","year":"2014","unstructured":"Mafirakureva N, Khoza S, Mvere DA, et al. Incidence and pattern of 12 years of reported transfusion adverse events in Zimbabwe: a retrospective analysis. Blood Transfus. 2014;12(3):362\u20137. https:\/\/doi.org\/10.2450\/2014.0156-13.","journal-title":"Blood Transfus"},{"issue":"3","key":"3225_CR28","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1097\/CCM.0b013e3181cc4d4b","volume":"38","author":"AP Vlaar","year":"2010","unstructured":"Vlaar AP, Binnekade JM, Prins D, van Stein D, Hofstra JJ, Schultz MJ, et al. Risk factors and outcome of transfusion-related acute lung injury in the critically ill: a nested case-control study. Crit Care Med. 2010;38(3):771\u20138. https:\/\/doi.org\/10.1097\/CCM.0b013e3181cc4d4b.","journal-title":"Crit Care Med"},{"issue":"2","key":"3225_CR29","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1590\/s1806-37132007000200016","volume":"33","author":"AJ Fabron","year":"2007","unstructured":"Fabron AJ, Lopes LB, Bordin JO. Transfusion-related acute lung injury. J Bras Pneumol. 2007;33(2):206\u201312. https:\/\/doi.org\/10.1590\/s1806-37132007000200016.","journal-title":"J Bras Pneumol"},{"issue":"8\u20139","key":"3225_CR30","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1007\/s00251-017-0989-3","volume":"69","author":"L D'Orsogna","year":"2017","unstructured":"D'Orsogna L, van den Heuvel H, van Kooten C, Heidt S, Claas F. Infectious pathogens may trigger specific Allo-HLA reactivity via multiple mechanisms. Immunogenetics. 2017;69(8\u20139):631\u201341. https:\/\/doi.org\/10.1007\/s00251-017-0989-3.","journal-title":"Immunogenetics."},{"issue":"2","key":"3225_CR31","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1016\/j.mayocp.2020.11.007","volume":"96","author":"JE Juskewitch","year":"2021","unstructured":"Juskewitch JE, Stubbs JR, Gandhi MJ. Elevated rate of HLA antibodies in male COVID-19 convalescent plasma donors: a risk factor for transfusion-related acute lung injury. Mayo Clin Proc. 2021;96(2):500\u20132. https:\/\/doi.org\/10.1016\/j.mayocp.2020.11.007.","journal-title":"Mayo Clin Proc"}],"container-title":["BMC Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12887-022-03225-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12887-022-03225-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12887-022-03225-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,22]],"date-time":"2022-03-22T04:03:52Z","timestamp":1647921832000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpediatr.biomedcentral.com\/articles\/10.1186\/s12887-022-03225-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,22]]},"references-count":31,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["3225"],"URL":"https:\/\/doi.org\/10.1186\/s12887-022-03225-1","relation":{},"ISSN":["1471-2431"],"issn-type":[{"value":"1471-2431","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,22]]},"assertion":[{"value":"13 August 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 March 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 March 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the ethics committee of Guangzhou Women and Children\u2019s Medical Center (Approval number: 2016102420). Signed informed consents were obtained from pediatric parents or guardians for high titer NAbs plasma treatment. All methods were performed in accordance with the provisions of the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that no competing interests exist.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"151"}}